Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Phase 1

Study of PIPE-791 for Subjects With Chronic Osteoarthritis Pain or Chronic Low Back Pain

NCT06810245 · View on ClinicalTrials.gov ↗

Study Summary

The primary goal of this clinical trial is to learn if PIPE-791 is safe and well-tolerated in adults with chronic osteoarthritis pain (COAP) or chronic low back pain (CLBP). The study will also explore whether PIPE-791 lowers pain in people with COAP or CLBP. Subjects will: * Complete a washout period to stop their current pain medications. * Take a daily dose of PIPE-791 or placebo for 4 weeks, then reverse treatment assignment for another 4 weeks. * Record pain levels and track dosing in a daily e-diary. * Visit the clinic for checkups and lab tests throughout the study. * Complete phone assessments during the treatment periods.

Interventions

  • DRUG Placebo
  • DRUG PIPE-791

Study Locations (5)

Arizona

  • Arizona Research Center — Phoenix

Georgia

  • Drug Studies America — Marietta

New York

  • Drug Trials America — Hartsdale

Pennsylvania

  • Altoona Center of Clinical Research — Duncansville

Utah

  • JBR Clinical Research — Salt Lake City

Trial Details

FieldValue
Enrollment Target 43 participants
Start Date 2025-02-04
Est. Completion 2026-01-20
Phase Phase 1

Sponsor

Contineum Therapeutics

2 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06810245

The ClinicalTrials.gov registry entry for NCT06810245 describes a study currently listed as completed. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Contineum Therapeutics, which has 2 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Chronic Low Back Pain appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06810245 reports 5 study locations spanning 5 distinct geographic areas — top geographies include Arizona, Georgia, New York. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06810245 about?

NCT06810245 is a clinical study titled "Study of PIPE-791 for Subjects With Chronic Osteoarthritis Pain or Chronic Low Back Pain". The primary goal of this clinical trial is to learn if PIPE-791 is safe and well-tolerated in adults with chronic osteoarthritis pain (COAP) or chronic low back pain (CLBP). The study will also explore whether PIPE-791 lowers pain in people with COAP or CLBP. Subjects will: * Complete a washout pe...

What is the current status of trial NCT06810245?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2025-02-04. Estimated completion is 2026-01-20.

What conditions does trial NCT06810245 study?

This clinical trial studies the following conditions: Chronic Low Back Pain, Chronic Osteoarthritis Pain. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06810245?

The interventions under investigation include: Placebo (DRUG), PIPE-791 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06810245?

This trial is sponsored by Contineum Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06810245 being conducted?

This trial has 5 study locations across Arizona, Georgia, New York, Pennsylvania, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial